BR112022010251A2 - Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta - Google Patents
Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento betaInfo
- Publication number
- BR112022010251A2 BR112022010251A2 BR112022010251A BR112022010251A BR112022010251A2 BR 112022010251 A2 BR112022010251 A2 BR 112022010251A2 BR 112022010251 A BR112022010251 A BR 112022010251A BR 112022010251 A BR112022010251 A BR 112022010251A BR 112022010251 A2 BR112022010251 A2 BR 112022010251A2
- Authority
- BR
- Brazil
- Prior art keywords
- alk5
- growth factor
- diseases
- compounds
- receptor
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003102 growth factor Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000009466 transformation Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000001575 pathological effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 abstract 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19383057 | 2019-11-28 | ||
| PCT/EP2020/083566 WO2021105317A1 (en) | 2019-11-28 | 2020-11-27 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010251A2 true BR112022010251A2 (pt) | 2022-09-06 |
Family
ID=68808255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010251A BR112022010251A2 (pt) | 2019-11-28 | 2020-11-27 | Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12297186B2 (https=) |
| EP (1) | EP4065572A1 (https=) |
| JP (2) | JP7808032B2 (https=) |
| KR (1) | KR20220107180A (https=) |
| CN (1) | CN114787145B (https=) |
| AR (1) | AR120578A1 (https=) |
| AU (1) | AU2020394531A1 (https=) |
| BR (1) | BR112022010251A2 (https=) |
| CA (1) | CA3160963A1 (https=) |
| ES (1) | ES3029608T1 (https=) |
| IL (1) | IL293388B2 (https=) |
| MX (1) | MX2022005843A (https=) |
| PH (1) | PH12022551177A1 (https=) |
| SA (1) | SA522432749B1 (https=) |
| WO (1) | WO2021105317A1 (https=) |
| ZA (1) | ZA202205149B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| TW202543626A (zh) | 2024-02-22 | 2025-11-16 | 西班牙商亞哥邁伯西班牙有限公司 | 新穎結晶相形式 |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3621540A1 (de) | 1986-06-27 | 1988-01-07 | Basf Ag | Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen |
| ATE291020T1 (de) | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| CA2720343A1 (en) | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| EP3283479B1 (en) * | 2015-04-01 | 2022-12-14 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| US20210002265A1 (en) | 2018-03-02 | 2021-01-07 | Université de Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-11-27 WO PCT/EP2020/083566 patent/WO2021105317A1/en not_active Ceased
- 2020-11-27 MX MX2022005843A patent/MX2022005843A/es unknown
- 2020-11-27 CA CA3160963A patent/CA3160963A1/en active Pending
- 2020-11-27 ES ES20811359T patent/ES3029608T1/es active Pending
- 2020-11-27 JP JP2022531434A patent/JP7808032B2/ja active Active
- 2020-11-27 BR BR112022010251A patent/BR112022010251A2/pt unknown
- 2020-11-27 PH PH1/2022/551177A patent/PH12022551177A1/en unknown
- 2020-11-27 IL IL293388A patent/IL293388B2/en unknown
- 2020-11-27 AR ARP200103298A patent/AR120578A1/es unknown
- 2020-11-27 KR KR1020227017493A patent/KR20220107180A/ko active Pending
- 2020-11-27 CN CN202080080848.3A patent/CN114787145B/zh active Active
- 2020-11-27 US US17/780,099 patent/US12297186B2/en active Active
- 2020-11-27 EP EP20811359.7A patent/EP4065572A1/en active Pending
- 2020-11-27 AU AU2020394531A patent/AU2020394531A1/en active Pending
-
2022
- 2022-05-10 ZA ZA2022/05149A patent/ZA202205149B/en unknown
- 2022-05-26 SA SA522432749A patent/SA522432749B1/ar unknown
-
2025
- 2025-05-06 US US19/200,279 patent/US20250333395A1/en active Pending
- 2025-07-10 JP JP2025116497A patent/JP2025163046A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114787145B (zh) | 2024-03-26 |
| IL293388B2 (en) | 2026-04-01 |
| AR120578A1 (es) | 2022-02-23 |
| ES3029608T1 (en) | 2025-06-24 |
| IL293388A (en) | 2022-07-01 |
| ZA202205149B (en) | 2025-06-25 |
| WO2021105317A1 (en) | 2021-06-03 |
| CA3160963A1 (en) | 2021-06-03 |
| AU2020394531A1 (en) | 2022-06-09 |
| PH12022551177A1 (en) | 2024-02-05 |
| JP2025163046A (ja) | 2025-10-28 |
| US12297186B2 (en) | 2025-05-13 |
| SA522432749B1 (ar) | 2025-05-12 |
| JP2023504795A (ja) | 2023-02-07 |
| IL293388B1 (en) | 2025-12-01 |
| US20250333395A1 (en) | 2025-10-30 |
| MX2022005843A (es) | 2022-07-19 |
| CN114787145A (zh) | 2022-07-22 |
| US20230025933A1 (en) | 2023-01-26 |
| EP4065572A1 (en) | 2022-10-05 |
| JP7808032B2 (ja) | 2026-01-28 |
| KR20220107180A (ko) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010251A2 (pt) | Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| BR112015014458A8 (pt) | compostos derivados de manose, seus intermediários, composição, uso e processos de preparação | |
| BR112015029972A2 (pt) | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto | |
| BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
| BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
| BR112014012129A8 (pt) | inibidores heterocíclicos de glutaminase | |
| BRPI0805826A2 (pt) | compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| BR112017004173A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica. | |
| BR112014032581A2 (pt) | inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: AGOMAB SPAIN, S.L.U. (ES) |